Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.

This article presents the findings of a retrospective multicenter study conducted in Japan on the use of enfortumab vedotin (EV) in patients with advanced urothelial carcinoma (UC). The study included 78 patients who had previously received platinum-containing chemotherapy and immune checkpoint inhibitors. The results showed that EV had a satisfactory response rate, although the progression-free survival (PFS) and overall survival (OS) were slightly shorter compared to clinical trials. High levels of C-reactive protein (CRP) and poor performance status (PS) were identified as key prognostic factors in these patients. The study acknowledges its limitations and suggests that further research is needed to confirm the findings. [Extracted from the article]